Completing this very essential milestone is a testament to the maturity of the Mevion firm and its ability to manufacture, install and support a safe and effective product, said Joseph Jachinowski, CEO of Mevion Medical Systems. We are very happy to receive this clearance from the FDA and today look forward to providing our customers and their patients access to this revolutionary device. This clearance enables users of the MEVION S250 to take care of immediately patients upon completion of their system installation. The first installing the MEVION S250 will soon be finished at the Kling Center for Proton Therapy at Barnes Jewish Medical center at Washington University in St.The objective of the studies was to confirm the procedure effect and security profile of lubiprostone capsules in Japanese CIC sufferers. The primary endpoint of the efficacy trial, a change from baseline in the amount of spontaneous bowel motions by the end of the initial week of treatment, was met by the patients acquiring 24-mcg lubiprostone twice a day time . Lubiprostone was shown to be well-tolerated and there have been no reported severe adverse effects in either trial. The secondary endpoints of the efficacy trial included the differ from baseline in the every week average number of SBMs at Weeks 2, 3 and 4, and scores in the short form 36 questionnaire and the irritable bowel syndrome quality of life questionnaire.